Results 231 to 240 of about 70,416 (256)

Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis

Cell Metabolism, 2020
Zan Huang, Zhi-Gang She, Lihua Zhu
exaly  

Sorafenib

Reactions Weekly, 2011
  +5 more sources

Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis

Annals of Oncology, 2013
Roberto Labianca, Lorenza Rimassa
exaly  

Sorafenib

Reactions Weekly, 2018
openaire   +1 more source

Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models

Journal of Hematology and Oncology, 2016
Tianqiang Song, HaiFang Yin, Ti Zhang
exaly  

Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial

Journal of Hepatology, 2018
Yi-Hsiang Huang, Weijing Sun, Alessandro Granito   +2 more
exaly  

Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells

Cell Death and Disease, 2013
Chen Pei-jer, Kuen-Feng Chen, Chen-Si Lin   +2 more
exaly  

Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial

Annals of Oncology, 2016
Tosiya Sato, S Nakamori, A Hagihara
exaly  

ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma

Acta Pharmacologica Sinica, 2020
Guo-dong Lu, Jing Zhou, Pan-Hong Chen
exaly  

Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings

Annals of Oncology, 2011
Giuseppe Procopio, D J Richel, M Staehler   +2 more
exaly